Oxytocinergic regulation of endogenous as well as drug-induced mood

Pharmacology Biochemistry and Behavior

Volumn 119, Issue , 2014, Pages 61-71

  Broadbear, J H ^a   Kabel, D ^a   Tracy, L ^a   Mak, P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

MDMA; Mood; Oxytocin; Pre clinical; Review; Vasopressin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ATOSIBAN; CARBETOCIN; CITALOPRAM; DESMOPRESSIN; DIAZEPAM; IMIPRAMINE; OXYTOCIN; OXYTOCIN RECEPTOR; RITANSERIN; SEROTONIN; VASOPRESSIN; VASOPRESSIN RECEPTOR;

AMYGDALOID NUCLEUS; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; BEHAVIOR CHANGE; DEPRESSION; DRUG DISCRIMINATION; DRUG SELF ADMINISTRATION; DRUG USE; ELEVATED T-MAZE TEST; GENERALIZED ANXIETY DISORDER; GENETIC DIFFERENCE; GLOBUS PALLIDUS; HIPPOCAMPUS; HUMAN; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; INTERPERSONAL STRESS; INTRAVENOUS DRUG ABUSE; LEARNED HELPLESSNESS TEST; LOCOMOTION; MOOD; MOOD DISORDER; NONHUMAN; NUCLEUS ACCUMBENS; OXYTOCIN BLOOD LEVEL; OXYTOCIN RELEASE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; REGULATORY MECHANISM; REVIEW; SEROTONIN RELEASE; SOCIAL COGNITION; TRANQUILIZING ACTIVITY;

MDMA; MOOD; OXYTOCIN; PRE-CLINICAL; REVIEW; VASOPRESSIN;

AFFECT; ANIMALS; HUMANS; OXYTOCIN;

EID: 84895509475     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.07.002     Document Type: Review

References (118)

1. K. Allott, and J. Redman Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)? Neurosci Biobehav Rev 31 2007 327 347
2. R.D. Ando, C. Adori, E. Kirilly, E. Molnar, G.G. Kovacs, L. Ferrington, P.A. Kelly, and G. Bagdy Acute SSRI-induced anxiogenic and brain metabolic effects are attenuated 6 months after initial MDMA-induced depletion Behav Brain Res 207 2010 280 289
3. R. Arletti, and A. Bertolini Oxytocin acts as an antidepressant in two animal models of depression Life Sci 41 1987 1725 1730
4. Australian Institute of Health and Welfare 2004 National Drug Strategy Household Survey: first results 2005 Australian Institute of Health and Welfare Canberra
5. Australian Institute of Health and Welfare Mental Health Services in Australia 2007-08 2010 Australian Institute of Health and Welfare Canberra
6. M.J. Bakermans-Kranenburg, and M.H. van IJzendoorn Oxytocin receptor (OXTR) and serotonin transporter (5-HTT) genes associated with observed parenting Soc Cogn Affect Neurosci 3 2008 128 134
7. S. Baron-Cohen, S. Wheelwright, J. Hill, Y. Raste, and I. Plumb The "Reading the Mind in the Eyes" test, revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism J Child Psychol Psychiatry 42 2001 241 251
8. J.A. Bartz, and E. Hollander Oxytocin and experimental therapeutics in autism spectrum disorders Prog Brain Res 170 2008 451 462
9. J.A. Bartz, J. Zaki, K.N. Oshsner, N. Bolger, A. Kolvezon, N. Ludwig, and J.E. Lydon Effects of oxytocin on recollections of maternal care and closeness Proc Natl Acad Sci U S A 107 2010 21371 21375
10. T. Baumgartner, E. Fehr, U. Fischbacher, M. Heinrichs, and A. Vonlanthen Oxytocin shapes the neural circuitry of trust and trust adaptation in humans Neuron 58 2008 639 650
11. C.A. Baylen, and H. Rosenberg A review of the acute subjective effects of MDMA/ecstasy Addiction 101 2006 933 947
12. S.L. Bealer, and W.R. Crowley Noradrenergic control of central oxytocin release during lactation in rats Am J Physiol Endocrinol Metab 274 1998 453 458
13. K. Beringer, and J.H. Broadbear Oxytocin as a mediator of the unique interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") in the rat Conference Proceedings of the Australian Psychological Society 2008 (September)
14. S.J. Bishop, J. Duncan, and A.D. Lawrence State anxiety modulation of the amygdala response to unattended threat-related stimuli J Neurosci 24 46 2004 10364 10368
15. J.H. Broadbear, B. Tunstall, and K. Beringer Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxy-methamphetamine (MDMA, "ecstasy") using a drug discrimination paradigm in the rat Addict Biol 16 2011 202 214
16. J.P. Burbach, L.J. Young, and J. Russell Oxytocin: synthesis, secretion and reproductive functions J.D. Neill, Knobil and Neill's physiology of reproduction 3rd ed. 2006 Pearson Education UK 3055 3128
17. C.S. Carter, E.M. Boone, H. Pournajafi-Nazarloo, and K.L. Bales Early experience, peptides and sex differences in development Dev Neurosci 31 2009 332 341
18. S. Chaviaras, P. Mak, D. Ralph, L. Krishnan, and J.H. Broadbear Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test Psychopharmacology 210 1 2010 35 43
19. K.J. Clemens, P.S. van Nieuwenhuyzen, K.M. Li, J.L. Cornish, G.E. Hunt, and I.S. McGregor MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat Psychopharmacology 173 2004 318 325
20. E.T. Cunningham, and P.E. Sawchenko Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus J Comp Neurol 274 1 1988 60 76
21. H.V. Curran Is MDMA ('ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research Neuropsychobiology 42 2000 34 41
22. H.V. Curran, and R.A. Travill Mood and cognitive effects of +/- 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low Addiction 92 1997 821 831
23. C. Dalla, P.M. Pitychoutis, N. Kokras, and Z. Papadopoulou-Daifoti Sex differences in animal models of depression and antidepressant response Basic Clin Pharmacol Toxicol 106 2009 226 233
24. R. Dantzer, R.-M. Bluthe, G.F. Koob, and M. Le Moal Modulation of social memory in male rats by neurohypophyseal peptides Psychopharmacology 91 1987 363 368
25. M. Davis The role of the amygdala in fear and anxiety Annu Rev Neurosci 15 1992 353 375
26. L. Degenhardt, B. Barker, and L. Topp Patterns of ecstasy use in Australia: findings from a national household survey Addiction 99 2 2004 187 195
27. L. Degenhardt, R. Bruno, and L. Topp Is ecstasy a drug of dependence? Drug Alcohol Depend 107 2010 1 10
28. M.A. Demitrack, and P.W. Gold Oxytocin: neurobiologic considerations and their implications for affective illness Prog Neuropsychopharmacol Biol Psychiatry 12 1988 S23 S51
29. M. Di Simplicio, R. Massey-Chase, P.J. Cowen, and C.J. Harmer Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers J Psychopharmacol 23 3 2009 241 248
30. G. Domes, M. Heinrichs, J. Glascher, C. Buchel, D.F. Braus, and S.C. Herpertz Oxytocin attenuates amygdala responses to emotional faces regardless of valence Biol Psychiatry 62 2007 1187 1190
31. Z.R. Donaldson, and L.J. Young Oxytocin, vasopressin, and the neurogenetics of sociality Science 322 2008 900 904
32. G.J. Dumont, F.C. Sweep, R. van der Steen, R. Hermsen, A.R. Donders, D.J. Touw, J.M. van Gerven, J.K. Buitelaar, and R.J. Verkes Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration Soc Neurosci 4 2009 359 366
33. M.A. Ellenbogen, A.-M. Linnen, C. Cardosa, and R. Joober Does oxytocin modulate mood and cortisol response to interpersonal stress? Implications for depression Biol Psychiatry 65 8(Suppl. 1) 2009 179S
34. M.A. Ellenbogen, A.-M. Linnen, C. Cardoso, and R. Joober Intranasal oxytocin impedes the ability to ignore task-irrelevant facial expressions of sadness in students with depressive symptoms Psychoneuroendocrinology 2012 10.1016/j.psyneuen.2012.06.016
35. T. Engstrom, T. Barth, P. Melin, and H. Vilhardt Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation Eur J Pharmacol 355 2-3 1998 203 210
36. R. Faria, A. Magalhaes, P.R.R. Monteiro, J. Gomes-Da-Silva, M.A. Tavares, and T. Summavielle () MDMA in adolescent male rats: decreased serotonin in the amygdala and behavioral effects in the elevated plus-maze test Ann N Y Acad Sci 1074 2006 643 649
37. D. Feifel, K. MacDonald, R. McKinney, N. Heisserer, and V. Serrano () A randomized, placebo controlled investigation of intranasal oxytocin in patients with anxiety Neuropsychopharmacology 36 2011 324 329
38. M.L. Forsling, J.K. Fallon, D. Shah, G.S. Tilbrook, D.A. Cowan, A.T. Kicman, and A.J. Hutt The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus Br J Pharmacol 135 3 2002 649 656
39. E. Frank, and R. Landgraf The vasopressin system - from antidiuresis to psychopathology Eur J Pharmacol 583 2008 226 242
40. A.T.Z. Frasch, A. Steiger, and G.F. Jirikowski Reduction of plasma oxytocin levels in patients suffering from major depression Adv Exp Med Biol 395 1995 257 258
41. G. Gimpl, and F. Fahrenholz The oxytocin receptor system: structure, function, and regulation Physiol Rev 81 2 2001 629 683
42. G. Gimpl, R. Postina, F. Fahrenholz, and T. Reinheimer Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin Eur J Pharmacol 510 2005 9 16
43. G.R. Greer, and R. Tolbert A method of conducting therapeutic sessions with MDMA J Psychoactive Drugs 30 4 1998 371 379
44. A.J. Guastella, S.L. Einfeld, K.M. Gray, N.J. Rinehart, B.J. Tonge, T.J. Lambert, and I.B. Hickie Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders Biol Psychiatry 67 2010 692 694
45. C.G. Gurtman, K.C. Morley, K.M. Li, G.E. Hunt, and I.S. McGregor Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion Eur J Pharmacol 446 2002 89 96
46. J. Hardt, and M. Rutter Validity of adult retrospective reports of adverse childhood experiences: review of the evidence J Child Psychol Psychiatry 45 2 2004 260 273
47. M. Heinrichs, G. Meinlschmidt, I. Neumann, S. Wagner, C. Kirschbaum, U. Ehlert, and D.H. Hellhammer Effect of suckling on hypothalamic-pituitary-adrenal axis responses to psychosocial stress in postpartum lacatating women J Clin Endocrinol Metab 86 2001 4798 4804
48. A.C. Huizink, R.F. Ferdinand, J. van der Ende, and F.C. Verhulst Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study Br Med J 332 2006 825 827
49. C.M. Hysek, G. Domes, and M.E. Liechti MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions Psychopharmacology 222 2012 293 302
50. E.J. Jaehne, I. Majumder, A. Salem, and R.J. Irvine Increased effects of 3,4-methylenedioxymethamphetamine (ecstasy) in a rat model of depression Addict Biol 16 1 2011 7 19
51. H. Jorgensen, M. Riis, U. Knigge, A. Kjaer, and J. Warberg Serotonin receptors involved in vasopressin and oxytocin secretion J Neuroendocrinol 15 2003 242 249
52. P. Kirsch, C. Esslinger, Q. Chen, D. Mier, S. Lis, S. Siddhanti, H. Gruppe, V.S. Mattay, B. Gallhofer, and A. Meyer-Lindenberg Oxytocin modulates neural circuitry for social cognition and fear in humans J Neurosci 25 49 2005 11489 11493
53. 11C]DASB and structural brain imaging study Brain 133 pt 6 2010 1779 1797
54. B. Kivell, D. Day, P. Bosch, S. Schenk, and J. Miller MDMA causes a redistribution of serotonin transporter from the cell surface to the intracellular compartment by a mechanism independent of phospho-p38-mitogen activated protein kinase activation Neuroscience 168 2010 82 95
55. I. Labuschagne, K.L. Phan, A. Wood, M. Angstadt, P. Chua, M. Heinrichs, J.C. Stout, and P.J. Nathan Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder Neuropharmacology 35 2010 2403 2413
56. R. Landgraf, and I.D. Neumann Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication Neuroendocrinology 25 2004 150 176
57. H.J. Lee, A.H. Macbeth, J.H. Pagani, and W.S. Young III Oxytocin: the great facilitator of life Prog Neurobiol 88 2009 127 151
58. R. Lieb, C.G. Schuetz, H. Pfister, K. von Sydow, and H.-U. Wittchen Mental disorders in ecstasy users: a prospective longitudinal investigation Drug Alcohol Depend 68 2002 195 207
59. G. Liebsch, C.T. Wotjak, R. Landgraf, and M. Engelmann Septal vasopressin modulates anxiety-related behaviour in rats Neurosci Lett 217 1996 101 104
60. M.E. Liechti, A. Gamma, and F.X. Vollenweider Gender differences in the subjective effects of MDMA Psychopharmacology 154 2001 161 168
61. J.S. Lonstein Regulation of anxiety during the postpartum period Front Neuroendocrinol 28 2007 115 141
62. P. Mak, C. Broussard, K. Vacy, and J.H. Broadbear Modulation of anxiety behaviour by peptidic oxytocin and vasopressin receptor ligands in the rat J Psychopharmacol 26 4 2012 532 542
63. O. Malkesman, and A. Weller Two different putative genetic animal models of childhood depression - a review Prog Neurobiol 88 3 2009 153 169
64. M. Manning, K. Miteva, S. Pancheva, S. Stoev, N.C. Wo, and W.Y. Chan Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with atosiban Int J Pept Protein Res 46 1995 244 252
65. I.S. McGregor, K.J. Clemens, G. Van der Plasse, K.M. Li, G.E. Hunt, F. Chen, and A.J. Lawrence Increased anxiety 3 months after brief exposure to MDMA ("ecstasy") in rats: association with altered 5-HT transporter and receptor density Neuropsychopharmacology 28 8 2003 1472 1484
66. I. Mechaly, F. Laurent, K. Portet, J.J. Serrano, and G. Cros Vasopressin V2 (SR121463A) and V1A (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity Eur J Pharmacol 383 1999 287 290
67. S.L. Meddle, G. Leng, J.R. Selvarajah, R.J. Bicknell, and J.A. Russell Direct pathways to the supraoptic nucleus from the brainstem and the main olfactory bulb are activated at parturition in the rat Neuroscience 101 4 2000 1013 1021
68. G. Meisenberg Short-term behavioral effects of posterior pituitary peptides in mice Peptides 2 1981 1 8
69. G. Meisenberg Short-term behavioural effects of neurohypophyseal hormones: pharmacological characteristics Neuropharmacology 21 1982 309 316
70. R.M. Milani, A.C. Parrott, J.J.D. Turner, and H.C. Fox Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users Addict Behav 29 2004 965 971
71. K.C. Morley, and I.S. McGregor (+/-)-3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats Eur J Pharmacol 408 2000 41 49
72. I. Neumann Brain oxytocin: a key regulator of emotional and social behaviours in both females and males J Neuroendocrinol 20 2008 858 865
73. A.A. Nierenberg, and E.C. Wright Evolution of remission as the new standard in the treatment of depression J Clin Psychiatry 60 22 1999 7 11
74. E. Nowakowska, K. Kus, T. Bobkiewicz-Kozlowska, and H. Hertmanowska Role of neuropeptides in antidepressant and memory improving effects of venlafaxine Pol J Pharmacol 54 2002 605 613
75. D. Nutt, L.A. King, W. Saulsbury, and C. Blakemore Development of a rational scale to assess the harm of drugs of potential misuse Lancet 369 9566 2007 1047 1053
76. R.P. Ogeil, S.M.W. Rajaratnam, J.R. Redman, and J.H. Broadbear Acute MDMA administration alters the distribution and circadian rhythm of wheel running activity in the rat Brain Res 1359 2010 128 136
77. R.P. Ogeil, S.M.W. Rajaratnam, J.G. Phillips, J.R. Redman, K.T. Ng, and J.H. Broadbear Ecstasy use and self-reported disturbances in sleep Hum Psychopharmacol Clin Exp 26 7 2011 508 516
78. R.P. Ogeil, D.J. Kennaway, M.D. Salkeld, S.M.W. Rajaratnam, and J.H. Broadbear MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei Psychopharmacology 220 4 2012 835 843
79. R.P. Ogeil, S.M.W. Rajaratnam, and J.H. Broadbear Male and female ecstasy users: Differences in patterns of use, sleep quality and mental health outcomes Drug and Alcohol Dependence 132 1-2 2013 223 230
80. T. Onaka, K. Ikeda, T. Yamashita, and K. Honda Facilitative role of endogenous oxytocin in noradrenaline release in the rat supraoptic nucleus Eur J Neurosci 18 2003 3018 3026
81. D.H. Overstreet The Flinders Sensitive Line rats: a genetic animal model of depression Neurosci Biobehav Rev 17 1 1993 51 68
82. D.H. Overstreet, and G. Griebel Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat Pharmacol Biochem Behav 82 2005 223 227
83. D. Overstreet, E. Friedman, A.A. Mathe, and G. Yadid The Flinders Sensitive Line rat: a selectively bred putative animal model of depression Neurosci Biobehav Rev 29 4-5 2005 739 759
84. T. Páleníček, M. Votava, V. Bubeníková , and J. Horáček Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats Physiol Behav 86 2005 546 553
85. A.C. Parrott MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress J Psychopharmacol 20 2 2006 147 163
86. A.C. Parrott, E. Sisk, and J.J. Turner Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users Drug Alcohol Depend 60 2000 105 110
87. B.J. Piper, J.B. Fraiman, and J.S. Meyer Repeated MDMA ("ecstasy") exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter levels Dev Psychobiol 47 2005 145 157
88. B.J. Piper, J.B. Fraiman, C.B. Owens, S.F. Ali, and J.S. Meyer Dissociation of the neurochemical and behavioural toxicology of MDMA ("ecstasy") by citalopram Neuropsychopharmacology 33 2008 1192 1205
89. R.D. Porsolt, L. Pichon, N. Blavet, and M. Jalfre Behavioural despair in rats: a new model sensitive to antidepressant treatments Eur J Pharmacol 47 1978 379 391
90. O. Pucilowski, D.H. Overstreet, A.H. Rezvani, and D.S. Janowsky Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression Physiol Behav 54 6 1993 1215 1220
91. J.S. Purba, W.J.G. Hoogendijk, M.A. Hofman, and D.F. Swaab Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression Arch Gen Psychiatry 53 2 1996 137 143
92. H. Rockliff, A. Karl, K. McEwan, J. Gilbert, M. Matos, and J. Gilbert Effects of intranasal oxytocin on 'compassion focused imagery' Emotion 11 6 2011 1388 1396
93. R. Rygula, N. Abumaria, G. Flugge, E. Fuchs, E. Ruther, and U. Havemann-Reinecke Anhedonia and motivational deficits in rats: impact of chronic social stress Behav Brain Res 162 2008 127 134
94. P.E. Sawchenko, L.W. Swanson, H.W.M. Steinbusch, and A.A.J. Verhofstad The distribution and cells of origin of serotonergic inputs to the paraventricular and supraoptic nuclei of the rat Brain Res 277 2 1983 355 360
95. S. Schenk, L. Hely, B. Lake, E. Daniela, D. Gittings, and D.C. Mash MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding Eur J Neurosci 26 11 2007 3229 3236
96. F. Schifano, L. Di Furia, G. Forza, N. Minicuci, and R. Bricolo MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients Drug Alcohol Depend 52 1998 85 90
97. H. Schwarzberg, G.L. Kovacs, G. Szabo, and G. Telegdy Intraventricular administration of vasopressin and oxytocin effects the steady-state levels of serotonin, dopamine and norepinephrine in rat brain Endocrinol Exp 15 1981 75 80
98. B. Sessa, and D.J. Nutt MDMA, politics and medical research: have we thrown the baby out with the bathwater? J Psychopharmacol 21 8 2007 787 791
99. M. Shayit, G. Yadid, D.H. Overstreet, and A. Weller 5-HT(1A) receptor subsensitivity in infancy and supersensitivity in adulthood in an animal model of depression Brain Res 980 2003 100 108
100. M.R. Skelton, J.A. Able, C.E. Grace, N.R. Herring, T.L. Schaefer, G.A. Gudelsky, C.V. Vorhees, and M.T. Williams (+/-)-3,4- Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks Neuropharmacology 55 7 2008 1121 1130
101. L. Strathearn, P. Fonagy, J.A. Amico, and P.R. Montague Adult attachment predicts maternal brain and peripheral oxytocin response to infant cues Neuropsychopharmacology 34 2009 2655 2666
102. H.R. Sumnall, J.C. Cole, and L. Jerome The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy J Psychopharmacol 20 2006 670 682
103. J.G. Tasker, C. Boudaba, D.A. Poulain, and D.T. Theodosis Cell biology of oxytocin and vasopressin neurons D.W. Pfaff, A.P. Arnold, A.M. Etgen, S.E. Fahrbach, R.T. Rubins, Hormones, brain and behaviour 2002 Academic Press London 811 842
104. The World Health Organisation report 2001 - mental health: new understanding, new hope http://www.who.int/whr/2001/en/whr01-ch2-en.pdf
105. M.R. Thompson, K.M. Li, K.J. Clemens, C.G. Gurtman, G.E. Hunt, and J.L. Cornish et al. Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('ecstasy') in rats Neuropsychopharmacology 29 4 2004 694 704
106. M.R. Thompson, P.D. Callaghan, G.E. Hunt, J.L. Cornish, and I.S. McGregor A role for oxytocin and 5-HT 1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine Neuroscience 146 2007 509 514
107. K. Uvnas-Moberg, E. Bjorkstrand, V. Hillegaart, and S. Ahlenius Oxytocin as a possible mediator of SSRI-induced antidepressant effects Psychopharmacology 142 1999 95 101
108. S.L. Verheyden, J. Hadfield, T. Calin, and H.V. Curran Sub-acute effects of MDMA (3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences Psychopharmacology 161 2002 23 32
109. P. Vienante, and M.J. Freund-Mercier Distribution of oxytocin- and vasopressin-binding sites in the rat extended amygdala: a histo-autoradiographic study J Comp Neurol 383 1997 305 325
110. D. Viviani, and R. Stoop Opposite effects of oxytocin and vasopressin on the emotional expression of the fear response Prog Brain Res 170 2008 207 218
111. Q.D. Walker, C.N. Williams, R.P. Jotwani, S.T. Waller, R. Francis, and C.M. Kuhn Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats Psychopharmacology 189 4 2007 435 445
112. E. Wallis, D.H. Overstreet, and A.D. Crocker Selective breeding for increased cholinergic function: increased serotonergic sensitivity Pharmacol Biochem Behav 31 1988 345 350
113. M.M. Weissman, and M. Olfson Depression in women: implications for health care research Science 269 1995 799 801
114. P. Willner Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS Neuropsychobiology 52 2005 90 110
115. P. Willner, I.R. Muscat, and M. Papp Chronic mild stress-induced anhedonia: a realistic animal model of depression Neurosci Biobehav Rev 16 1992 525 534
116. K. Wolff, E.M. Tsapakis, A.R. Winstock, D. Hartley, D. Holt, M.L. Forsling, and K.J. Aitchison Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population J Psychopharmacol 20 2006 400 410
117. M. Yoshida, Y. Takayanagi, K. Inoue, T. Kimura, L.J. Young, T. Onaka, and K. Nishimori Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice J Neurosci 29 7 2009 2259 2271
118. L.J. Young, and Z. Wang The neurobiology of pair bonding Nat Neurosci 7 2004 1048 1054